{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:20:38Z","timestamp":1790734838709,"version":"4.1.0"},"reference-count":89,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The incidence of both diabetes mellitus type 2 and heart failure is rapidly growing, and the diseases often coexist. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a new antidiabetic drug class that mediates epithelial glucose transport at the renal proximal tubules, inhibiting glucose absorption\u2014resulting in glycosuria\u2014and therefore improving glycemic control. Recent trials have proven that SGLT2i also improve cardiovascular and renal outcomes, including reduced cardiovascular mortality and fewer hospitalizations for heart failure. Reduced preload and afterload, improved vascular function, and changes in tissue sodium and calcium handling may also play a role. The expected paradigm shift in treatment strategies was reflected in the most recent 2021 guidelines published by the European Society of Cardiology, recommending dapagliflozin and empagliflozin as first-line treatment for heart failure patients with reduced ejection fraction. Moreover, the recent results of the EMPEROR-Preserved trial regarding empagliflozin give us hope that there is finally an effective treatment for patients with heart failure with preserved ejection fraction. This review aims to assess the efficacy and safety of these new anti-glycemic oral agents in the management of diabetic and heart failure patients.<\/jats:p>","DOI":"10.3390\/jcm11061470","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T12:35:37Z","timestamp":1646742937000},"page":"1470","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure\u2014A Concise Review"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8570-1812","authenticated-orcid":false,"given":"Daria M.","family":"Keller","sequence":"first","affiliation":[{"name":"Ist Department of Cardiology, Poznan University of Medical Sciences, 61-848 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8204-8205","authenticated-orcid":false,"given":"Natasha","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Cardiology Department, Lancashire Teaching Hospitals NHS Foundation Trust, Preston PR2 9HT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4576-7323","authenticated-orcid":false,"given":"Hamza","family":"Tariq","sequence":"additional","affiliation":[{"name":"Cardiology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry CV2 2DX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0683-7576","authenticated-orcid":false,"given":"Malsha","family":"Walgamage","sequence":"additional","affiliation":[{"name":"Center for Medical Education in English, Poznan University of Medical Sciences, 60-512 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9819-7096","authenticated-orcid":false,"given":"Thilini","family":"Walgamage","sequence":"additional","affiliation":[{"name":"Center for Medical Education in English, Poznan University of Medical Sciences, 60-512 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1242-1422","authenticated-orcid":false,"given":"Azad","family":"Mohammed","sequence":"additional","affiliation":[{"name":"Center for Medical Education in English, Poznan University of Medical Sciences, 60-512 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4448-8768","authenticated-orcid":false,"given":"Jadzia Tin-Tsen","family":"Chou","sequence":"additional","affiliation":[{"name":"Ist Department of Cardiology, Poznan University of Medical Sciences, 61-848 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4048-6247","authenticated-orcid":false,"given":"Marta","family":"Ka\u0142u\u017cna-Oleksy","sequence":"additional","affiliation":[{"name":"Ist Department of Cardiology, Poznan University of Medical Sciences, 61-848 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2630-5016","authenticated-orcid":false,"given":"Maciej","family":"Lesiak","sequence":"additional","affiliation":[{"name":"Ist Department of Cardiology, Poznan University of Medical Sciences, 61-848 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0545-3370","authenticated-orcid":false,"given":"Ewa","family":"Straburzy\u0144ska-Migaj","sequence":"additional","affiliation":[{"name":"Ist Department of Cardiology, Poznan University of Medical Sciences, 61-848 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.diabres.2017.03.024","article-title":"IDF Diabetes Atlas: Global Estimates for the Prevalence of Diabetes for 2015 and 2040","volume":"128","author":"Ogurtsova","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.15420\/cfr.2016:20:2","article-title":"Heart Failure in Patients with Diabetes Mellitus","volume":"3","author":"Rosano","year":"2017","journal-title":"Card. Fail. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1001\/archinte.168.15.1699","article-title":"The Hemoglobin A1c Level as a Progressive Risk Factor for Cardiovascular Death, Hospitalization for Heart Failure, or Death in Patients with Chronic Heart Failure: An Analysis of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program","volume":"168","author":"Gerstein","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"695792","DOI":"10.3389\/fmed.2021.695792","article-title":"The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms","volume":"8","author":"Salvatore","year":"2021","journal-title":"Front. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.21037\/amj.2020.03.03","article-title":"Global Epidemiology and Future Trends of Heart Failure","volume":"5","author":"Lippi","year":"2020","journal-title":"AME Med. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2174\/0929867324666170530075533","article-title":"Update on Cardiovascular Effects of Older and Newer Anti-Diabetic Medications","volume":"25","author":"Eleftheriadou","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1210\/er.2010-0029","article-title":"Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes","volume":"32","author":"Norton","year":"2011","journal-title":"Endocr. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.2337\/dc13-0387","article-title":"Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects with Type 2 Diabetes","volume":"36","author":"DeFronzo","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1042\/bj0251128","article-title":"The Relation of Glycosuria to Glycaemia and the Determination of the Renal Threshold for Glucose","volume":"25","author":"Himsworth","year":"1931","journal-title":"Biochem. J."},{"key":"ref_15","unstructured":"Terjung, R. (2012). Uriniferous Tubule: Structural and Functional Organization. Comprehensive Physiology, John Wiley & Sons, Inc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0022-5320(66)80060-6","article-title":"Observations on the Segmentation of the Proximal Tubule in the Rat Kidney","volume":"16","author":"Maunsbach","year":"1966","journal-title":"J. Ultrastruct. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1005632012591","article-title":"Glucose Transporters: Structure, Function and Consequences of Deficiency","volume":"23","author":"Brown","year":"2000","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule","volume":"22","author":"Vallon","year":"2011","journal-title":"JASN"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00424-003-1202-0","article-title":"The Sodium\/Glucose Cotransport Family SLC5","volume":"447","author":"Wright","year":"2004","journal-title":"Pflug. Arch."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"11753","DOI":"10.1073\/pnas.1733027100","article-title":"A Glucose Sensor Hiding in a Family of Transporters","volume":"100","author":"Hirayama","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/ki.1997.348","article-title":"Immunodissection of the Human Proximal Nephron: Flow Sorting of S1S2S3, S1S2 and S3 Proximal Tubular Cells","volume":"52","author":"Helbert","year":"1997","journal-title":"Kidney Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1038\/sj.ki.5002383","article-title":"Regulatory Mechanisms of Na+\/Glucose Cotransporters in Renal Proximal Tubule Cells","volume":"72","author":"Lee","year":"2007","journal-title":"Kidney Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/dom.12073","article-title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following 4 Weeks\u2019 Treatment with Empagliflozin Once Daily in Patients with Type 2 Diabetes","volume":"15","author":"Heise","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/cpdd.16","article-title":"Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects: Clinical Pharmacology in Drug Development","volume":"2","author":"Seman","year":"2013","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.2337\/db17-0100","article-title":"Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals with Type 2 Diabetes","volume":"66","author":"Daniele","year":"2017","journal-title":"Diabetes"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1161\/CIRCULATIONAHA.117.029529","article-title":"Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients with Type 2 Diabetes Mellitus","volume":"136","author":"Striepe","year":"2017","journal-title":"Circulation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of Empagliflozin on Blood Pressure and Markers of Arterial Stiffness and Vascular Resistance in Patients with Type 2 Diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.lfs.2018.01.032","article-title":"The Anti-Diabetic Drug Dapagliflozin Induces Vasodilation via Activation of PKG and Kv Channels","volume":"197","author":"Li","year":"2018","journal-title":"Life Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"107832","DOI":"10.1016\/j.pharmthera.2021.107832","article-title":"Endothelial Function and Dysfunction: Impact of Sodium-Glucose Cotransporter 2 Inhibitors","volume":"224","author":"Ugusman","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Salvatore, T., Caturano, A., Galiero, R., Di Martino, A., Albanese, G., Vetrano, E., Sardu, C., Marfella, R., Rinaldi, L., and Sasso, F.C. (2021). Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function. Biomedicines, 9.","DOI":"10.3390\/biomedicines9101356"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/17425255.2019.1588886","article-title":"Metabolism of the Failing Heart and the Impact of SGLT2 Inhibitors","volume":"15","author":"Zafar","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/ehf2.12336","article-title":"Empagliflozin Reduces Ca\/Calmodulin-Dependent Kinase II Activity in Isolated Ventricular Cardiomyocytes: Empagliflozin Reduces CaMKII Activity","volume":"5","author":"Mustroph","year":"2018","journal-title":"ESC Heart Fail."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a Selective SGLT2 Inhibitor, Attenuated Cardiac Fibrosis by Regulating the Macrophage Polarization via STAT3 Signaling in Infarcted Rat Hearts","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 Inhibitors: Mechanisms of Cardiovascular Benefit beyond Glycaemic Control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Hou, Y.-C., Zheng, C.-M., Yen, T.-H., and Lu, K.-C. (2020). Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21217833"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/ehf2.12345","article-title":"Empagliflozin, Calcium, and SGLT1\/2 Receptor Affinity: Another Piece of the Puzzle","volume":"5","author":"Anker","year":"2018","journal-title":"ESC Heart Fail."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An Update on Sodium-Glucose Co-Transporter-2 Inhibitors for the Treatment of Diabetes Mellitus","volume":"24","author":"Hsia","year":"2016","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.2147\/DMSO.S212003","article-title":"Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician\u2019s Guide","volume":"12","author":"Simes","year":"2019","journal-title":"DMSO"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2337\/ds16-0030","article-title":"A Review of the Efficacy and Safety of Sodium\u2013Glucose Cotransporter 2 Inhibitors: A Focus on Diabetic Ketoacidosis","volume":"30","author":"Zurek","year":"2017","journal-title":"Diabetes Spectr."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","article-title":"Efficacy and Safety of Canagliflozin Monotherapy in Subjects with Type 2 Diabetes Mellitus Inadequately Controlled with Diet and Exercise","volume":"15","author":"Cefalu","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1185\/03007995.2013.850066","article-title":"Long-Term Efficacy and Safety of Canagliflozin Monotherapy in Patients with Type 2 Diabetes Inadequately Controlled with Diet and Exercise: Findings from the 52-Week CANTATA-M Study","volume":"30","author":"Cefalu","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/ijcp.12322","article-title":"Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Sulphonylurea: A Randomised Trial","volume":"67","author":"Wilding","year":"2013","journal-title":"Int. J. Clin. Pract."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2337\/dc15-1736","article-title":"Initial Combination Therapy with Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Na\u00efve Type 2 Diabetes","volume":"39","author":"Rosenstock","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00228-015-1923-y","article-title":"Efficacy and Tolerability of Canagliflozin as Add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus: A Meta-Analysis","volume":"71","author":"Yang","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","article-title":"Efficacy and Safety of Canagliflozin Compared with Placebo and Sitagliptin in Patients with Type 2 Diabetes on Background Metformin Monotherapy: A Randomised Trial","volume":"56","author":"Januszewicz","year":"2013","journal-title":"Diabetologia"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/dom.12273","article-title":"Efficacy and Safety of Canagliflozin over 52 Weeks in Patients with Type 2 Diabetes on Background Metformin and Pioglitazone","volume":"16","author":"Forst","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12933-016-0407-4","article-title":"Efficacy and Safety of Canagliflozin in Combination with Insulin: A Double-Blind, Randomized, Placebo-Controlled Study in Japanese Patients with Type 2 Diabetes Mellitus","volume":"15","author":"Inagaki","year":"2016","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin Monotherapy in Type 2 Diabetic Patients with Inadequate Glycemic Control by Diet and Exercise: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of Dapagliflozin in Patients with Type 2 Diabetes Who Have Inadequate Glycaemic Control with Metformin: A Randomised, Double-Blind, Placebo-Controlled Trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1742-1241.2012.02911.x","article-title":"Dapagliflozin, Metformin XR, or Both: Initial Pharmacotherapy for Type 2 Diabetes, a Randomised Controlled Trial: T2DM: Dapagliflozin, Metformin XR, or Both","volume":"66","author":"Henry","year":"2012","journal-title":"Int. J. Clin. Pract."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc11-0606","article-title":"Dapagliflozin versus Glipizide as Add-on Therapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control with Metformin: A Randomized, 52-Week, Double-Blind, Active-Controlled Noninferiority Trial","volume":"34","author":"Nauck","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"EMPA-REG MONO trial investigators Empagliflozin Monotherapy with Sitagliptin as an Active Comparator in Patients with Type 2 Diabetes: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"1","author":"Roden","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/dc13-2105","article-title":"Empagliflozin as Add-On to Metformin in Patients with Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"37","author":"Merker","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.4103\/2230-8210.94253","article-title":"Infections in Patients with Diabetes Mellitus: A Review of Pathogenesis","volume":"16","author":"Casqueiro","year":"2012","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1099\/00222615-48-6-535","article-title":"Effect of Glucose and PH on Uropathogenic and Non-Uropathogenic Escherichia Coli: Studies with Urine from Diabetic and Non-Diabetic Individuals","volume":"48","author":"Geerlings","year":"1999","journal-title":"J. Med. Microbiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jdiacomp.2012.06.008","article-title":"Incidence of Urinary Tract Infection among Patients with Type 2 Diabetes in the UK General Practice Research Database (GPRD)","volume":"26","author":"Hirji","year":"2012","journal-title":"J. Diabetes Complicat."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.diabres.2013.12.052","article-title":"Genital and Urinary Tract Infections in Diabetes: Impact of Pharmacologically-Induced Glucosuria","volume":"103","author":"Geerlings","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/dom.13531","article-title":"Comparative Risk of Genital Infections Associated with Sodium-Glucose Co-Transporter-2 Inhibitors","volume":"21","author":"Dave","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1038\/s41598-017-02733-w","article-title":"Effects of SGLT2 Inhibitors on UTIs and Genital Infections in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern with SGLT2 Inhibitors","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2337\/dc16-2724","article-title":"Renal Handling of Ketones in Response to Sodium\u2013Glucose Cotransporter 2 Inhibition in Patients with Type 2 Diabetes","volume":"40","author":"Ferrannini","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Palmiero, G., Cesaro, A., Vetrano, E., Pafundi, P.C., Galiero, R., Caturano, A., Moscarella, E., Gragnano, F., Salvatore, T., and Rinaldi, L. (2021). Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115863"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1161\/CIRCULATIONAHA.118.036459","article-title":"Cardiovascular Effects of Treatment with the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients","volume":"139","author":"Nielsen","year":"2019","journal-title":"Circulation"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e124079","DOI":"10.1172\/jci.insight.124079","article-title":"The Failing Heart Utilizes 3-Hydroxybutyrate as a Metabolic Stress Defense","volume":"4","author":"Horton","year":"2019","journal-title":"JCI Insight"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.diabres.2017.04.017","article-title":"Effects of SGLT-2 Inhibitors on Diabetic Ketoacidosis: A Meta-Analysis of Randomised Controlled Trials","volume":"130","author":"Monami","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/dom.13611","article-title":"A Safety Update on Sodium Glucose Co-transporter 2 Inhibitors","volume":"21","author":"Fitchett","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/dom.12307","article-title":"Efficacy and Safety of Empagliflozin for Type 2 Diabetes: A Systematic Review and Meta-Analysis","volume":"16","author":"Liakos","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","article-title":"Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Blood Pressure: A Systematic Review and Meta-Analysis","volume":"8","author":"Baker","year":"2014","journal-title":"J. Am. Soc. Hypertens."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"m2812","DOI":"10.1136\/bmj.m2812","article-title":"Risk of Amputation with Canagliflozin across Categories of Age and Cardiovascular Risk in Three US Nationwide Databases: Cohort Study","volume":"370","author":"Fralick","year":"2020","journal-title":"BMJ"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes: Results from the CANVAS Program Randomised Clinical Trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/ejhf.1536","article-title":"Evaluation of the Effect of Sodium-Glucose Co-Transporter 2 Inhibition with Empagliflozin on Morbidity and Mortality of Patients with Chronic Heart Failure and a Reduced Ejection Fraction: Rationale for and Design of the EMPEROR-Reduced Trial","volume":"21","author":"Packer","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 Inhibitors in Patients with Heart Failure with Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1161\/CIRCULATIONAHA.120.051122","article-title":"Two Tales: One Story: EMPEROR-Reduced and DAPA-HF","volume":"142","author":"Verma","year":"2020","journal-title":"Circulation"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 Inhibitors for Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Cardiovascular Outcome Trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 Inhibitors with Cardiovascular and Kidney Outcomes in Patients with Type 2 Diabetes: A Meta-Analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12933-019-0899-9","article-title":"Class Effect for SGLT-2 Inhibitors: A Tale of 9 Drugs","volume":"18","author":"Giugliano","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIRCULATIONAHA.120.052926","article-title":"How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?: A Redefinition of Evidence-Based Medicine","volume":"143","author":"McMurray","year":"2021","journal-title":"Circulation"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Severino, P., D\u2019Amato, A., Prosperi, S., Costi, B., Angotti, D., Birtolo, L.I., Chimenti, C., Lavalle, C., Maestrini, V., and Mancone, M. (2021). Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: The Best Timing for the Right Patient. Heart Fail. Rev., ahead of print.","DOI":"10.1007\/s10741-021-10170-1"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/6\/1470\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:33:47Z","timestamp":1760135627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/6\/1470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,8]]},"references-count":89,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["jcm11061470"],"URL":"https:\/\/doi.org\/10.3390\/jcm11061470","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,8]]}}}